Nintedanib

• AURA-IPF: A Randomized Phase 2 Study to evaluate the safety and efficacy of AP02 (nintedanib solution) in IPF Recruiting
  2025-523431-19-00 Phase II 3 countries Avalyn Pharma Inc.
• NUCastle - Nintedanib treatment in Unicentric Castleman disease Recruiting
  2023-510253-42-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• Assessment of the effect of Wharton's jelly mesenchymal stem cell preparation (WJMSCs) in the treatment of fibrotic interstitial lung diseas… Recruiting
  2024-514433-38-00 Phase I/II 1 country Medical University Of Gdansk
• LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting
  2022-502706-33-00 Phase IV 1 country Grupo Espanol De Investigacion En Cancer De Mama
• Study on efficacy of nintedanib for treatment of epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients - EPISTOP Ended
  2024-518886-89-00 Phase II 1 country Hospices Civils De Lyon
• clinical trial evaluating the efficacy of nintedanib with tocilizumab compared to standard treatment in patients with systemic sclerosis and… Ended
  2024-517005-85-00 Phase III 1 country Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. E…
• A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON) Ended
  2024-515743-27-00 Phase III 8 countries Boehringer Ingelheim International GmbH
• Pragmatic management of progressive disease in idiopathic pulmonary fibrosis Ended
  2024-511427-34-00 Phase III 1 country Hospices Civils De Lyon

Showing 1–8 of 8 trials